Sanofi SA (SAN) Quote - XPAR | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Undervalued Sanofi Posts Solid Q3, Buoyed by Well-Positioned Dupixent and Developing Pipeline

Sector Director Damien Conover

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA | Oct 28, 2021

Undervalued Sanofi reported solid third-quarter results that were slightly better than our expectations, but we don’t expect any change to our fair value estimate based on the minor outperformance. We believe the market continues to underappreciate the strength of immunology drug Dupixent and the developing pipeline that fortifies the firm’s wide moat.

Read Full Analysis

Company Profile

Business Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 8% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Contact

54, Rue La Boetie
Paris, 75008, France

T +33 153774000

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Jun 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type —

Employees 99,412

Related

Stock Analyst Update

Drug Pricing Executive Orders Not Likely to Affect FVEs

We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.

Stock Strategist Industry Reports

Coronavirus Has Limited Impact on Big Pharma and Big Biotech

Moats, valuations, and dividends look attractive in the market pullback.

Quarter-End Insights

Makings of a Wide Moat in Diabetes Care

Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

Quarter-End Insights

An Uneasy Calm for European Markets in 1Q

The markets took a stream of negative news and weak economic growth indicators in stride during the first quarter.

Quarter-End Insights

Strength Emerging in the Health-Care Sector

The health-care sector rally looks poised to continue.

Stock Strategist Industry Reports

Finding Moats in Big Pharma's Consumer Health Units

We believe breakups could unlock value for big pharma shareholders.

Stock Strategist Industry Reports

Trends So Far in Big Pharma's Fourth Quarter

We're seeing cost cutting, conservative forecasts, and slow new drug launches.

Stock Strategist Industry Reports

The 2010 Outlook for Big Pharma Stocks

Reform or no reform, the pharmaceutical industry is well-positioned.

Stock Strategist

Which Pharma Pipelines Rank Best?

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.

Stock Strategist Industry Reports

Which Pharma Pipelines Rank Best?

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.

Stock Strategist Industry Reports

Improved Outlook for Big Pharma Stocks in 2009

While challenges remain, we expect Big Pharma to perform well in 2009.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.